CTOR (Citius Oncology Inc) קצב צמיחת רווח למניה בשנה הנוכחית

Citius Oncology, Inc. (CTOR) attracts leading biochemists through a stock option system, completely eliminating employee turnover. The business possesses absolute macro-resilience, as demand for oncology drugs is independent of economic cycles. Future revenues rely on the success of T-cell lymphoma therapy, which is confirmed by year-over-year EPS dynamics, where the latest figure stands at -35.40.

This indicator calculates the percentage deviation of current earnings per share from the same period last year, allowing for an objective assessment of net yield dynamics without the influence of emotional factors. For Citius Oncology, Inc. (CTOR), which has no commercial sales and incurs high clinical trial costs, the current EPS YoY change reflects only the rate of investor capital burn.